The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome.

Flavia Campos Corgosinho, Aline de Piano, Priscila L Sanches, Raquel M Campos, Patricia L Silva, June Carnier, Lila M Oyama, Lian Tock, Sergio Tufik, Marco T de Mello, Ana R Dâmaso

Journal: Inflammation 2012;35(3):944-51

PMID: 22038064

Full Text on Springer View on PubMed

Abstract

Obesity is a chronic inflammatory disease and is considered a risk factor for metabolic syndrome. In this study, 57 obese adolescents with and without metabolic syndrome underwent 1 year of weight loss therapy. At baseline, the metabolic syndrome (MS) patients presented higher values of PAI-1 than the non-metabolic syndrome patients (n-MS). After therapy, significant improvements in anthropometrics and biochemical, inflammatory, and neuroendocrine variables were observed in both groups. However, the n-MS group presented better results than the MS group. Indeed, we found positive correlations in both groups between PAI-1 and neuropeptide Y (NPY) and between PAI-1 and NPY/AgRP. Inflammatory biomarkers may thus play a role in energy balance. The clinical trial registration number is NCT01358773.

Address: Post-Graduation Program of Nutrition, Paulista Medicine School, Universidade Federal de São Paulo, Rua Franscisco de Castro 93, São Paulo, 04020-050, Brazil. [email protected]

DOI: 10.1007/s10753-011-9397-2

Link outs

Free resources

Medical:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-1150

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s10753-011-9397-2

MeSH Terms: Adiponectin, Adiposity, Adolescent, Agouti-Related Protein, Body Composition, Body Mass Index, Energy Metabolism, Exercise, Female, Humans, Inflammation, Male, Metabolic Syndrome, Neuropeptide Y, Obesity, Plasminogen Activator Inhibitor 1, Weight Reduction Programs, Young Adult